 "Bharat Biotech, Covaxin")
Indian vaccine maker Bharat Biotech said on Monday it has submitted an application to the country's drug regulator to conduct a late-stage trial for a booster dose of its intranasal COVID-19 vaccine.
Indian COVID-19 vaccine makers are lobbying the government to authorise boosters as supplies have far outstripped demand, but the health ministry said there is no immediate plan to approve boosters and the priority remains complete vaccination of eligible adults.
"We have submitted phase 3 clinical trial application to DCGI (Drugs Controller General of India)," a Bharat Biotech spokesperson said in a statement, adding that an intranasal vaccine as
Disclaimer: No Business Standard Journalist was involved in creation of this content
